Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-D101 in DLL3-Positive Relapsed/Refractory Small Cell Lung Cancer
NCT07246304Phase 1Recruiting
- Sponsor
- TCRCure Biotech
- Start
- Jun 2026
- Primary completion
- Nov 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TC-D101 in small cell lung cancer (SCLC), sponsored by TCRCure Biotech. Primary endpoint: Safety of TC-D101 CAR-T cells at 24 months. Started Jun 2026; status: recruiting.
02
Drugs
TC-D101
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07246304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07246304.